With a comprehensive collaborative and supportive infrastructure, Chongqing possesses a complete pharmaceutical industry ecosystem. (Photo/Chongqing Morning Post)
Chongqing is a nationally significant hub for the biomedical industry, a key export base for traditional Chinese medicine (TCM) services, a high-tech industrialization base for national biomedical materials, and a nationally recognized innovation drug incubation base. With a comprehensive collaborative and supportive infrastructure, the city possesses a complete pharmaceutical industry ecosystem.
Key companies include Chongqing Zhifei Biological Products Co., Ltd., Chongqing Taiji Industry(Group), Hualan Bio, Zybio, YaoPharma, Porton Pharma Solutions, and Zein Biotechnology. Chongqing possesses achievements like the world’s first “High-Intensity Focused Ultrasound Tumor Treatment System,” the world’s first “Intelligent Capsule Endoscopy” with controllable posture, and the world’s first officially approved recombinant subunit COVID-19 vaccine. The city has become a significant growth driver for China’s biomedical industry.
Key business and industrial parks
These include Chongqing International Biological Park, Chongqing High-tech Industrial Development Zone, Liangjiang New Area, Dadukou District, Fuling District, and Changshou District.
Key development focus and investment areas
Biotechnological drugs, encompassing monoclonal antibody drugs, gene engineering drugs, probiotics, novel vaccines, and new blood products; chemical drugs for prevalent diseases, geriatric diseases, and rare diseases; modern TCM with independent intellectual property; and secondary development products of TCM.
The information is sourced from Investing Chongqing (2023). This article is updated on February 18, 2024.